Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) — Sensorium Therapeutics (Sensorium), a biotechnology company translating insights…
News
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
Kane Biotech Announces Closing of Fully Subscribed Private Placement Offering and Amendments to its Credit Facility
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG,…
Kane Biotech Announces Closing of Fully Subscribed Private Placement Offering and Amendments to its Credit Facility
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG,…
Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity
MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), a leading fully integrated…
Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity
MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), a leading fully integrated…
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
CLEVELAND, Sept. 12, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the…
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
CLEVELAND, Sept. 12, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the…
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Top-line 48-week results from the trial expected Q4 2023 GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE…
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Top-line 48-week results from the trial expected Q4 2023 GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE…
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) — Company hosts 1H 2023 Financial Results and Business…
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) — Company hosts 1H 2023 Financial Results and Business…
Repligen Appoints Jason K. Garland as Chief Financial Officer
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company…
Repligen Appoints Jason K. Garland as Chief Financial Officer
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company…
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
Follows the recommendation from ISS to vote FOR the transaction BOSTON, Sept. 12, 2023 (GLOBE…
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
Follows the recommendation from ISS to vote FOR the transaction BOSTON, Sept. 12, 2023 (GLOBE…
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and…
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and…
Glen Clark, business leader and former Premier of British Columbia, joins Board of Tersa Earth Innovations Inc.
Glen Clark Portrait of Glen Clark, appointed to Board of Directors, Tersa Earth Innovations Inc.,…